WALDENCAST ACQUISITION CORP

NASDAQ: WALD (Waldencast plc)

最近更新时间: 18 Feb, 1:11PM

1.77

-0.05 (-2.75%)

前收盘价格 1.82
收盘价格 1.80
成交量 21,163
平均成交量 (3个月) 102,216
市值 219,402,464
价格/销量 (P/S) 0.660
股市价格/股市净资产 (P/B) 0.400
52周波幅
1.45 (-18%) — 3.54 (100%)
利润日期 17 Mar 2026
营业毛利率 -15.50%
营业利益率 (TTM) -18.31%
稀释每股收益 (EPS TTM) -0.390
季度收入增长率 (YOY) 30.80%
总债务/股东权益 (D/E MRQ) 24.95%
流动比率 (MRQ) 1.35
营业现金流 (OCF TTM) -8.82 M
杠杆自由现金流 (LFCF TTM) 8.34 M
资产报酬率 (ROA TTM) -3.32%
股东权益报酬率 (ROE TTM) -6.49%

市场趋势

短期 中期
行业 Household & Personal Products (US) 混合的 看跌
Household & Personal Products (全球的) 混合的 看跌
股票 Waldencast plc 看跌 看跌

AIStockmoo 评分

-0.8
分析师共识 -0.5
内部交易活动 NA
价格波动 -2.0
技术平均移动指标 0.0
技术振荡指标 -0.5
平均 -0.75

相关股票

股票 市值 DY P/E(TTM) P/B
WALD 219 M - - 0.400
NWL 2 B 5.96% - 0.770
HELE 420 M - - 0.480
EWCZ 313 M - 22.00 2.16
UG 33 M 6.86% 16.95 2.87
DSY 16 M - - 462.91

Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.

部门 Consumer Defensive
行业 Household & Personal Products
投资方式 Small Value
内部持股比例 56.95%
机构持股比例 25.62%

所有权

姓名 日期 持有股份
Zeno Equity Partners Llp 31 Dec 2025 12,252,580
Milestones Administradora De Recursos Ltda. 31 Dec 2025 2,425,677
52周波幅
1.45 (-18%) — 3.54 (100%)
2.00 (12.99%)
总计 1 购买
公司 日期 目标价格 调整类型 价格@调整类型
Jefferies 14 Jan 2026 2.00 (12.99%) 购买 1.63

该时间范围内无数据。

日期 类型 细节
06 Feb 2026 公告 Obagi Medical and DermFx Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
05 Feb 2026 公告 Obagi Medical and Moxie Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
03 Feb 2026 公告 Obagi Medical Introduces New Lip Therapy Protocol Designed to Resurface, Replenish, and Protect
30 Jan 2026 公告 Obagi Medical and VIO Med Spa Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
28 Jan 2026 公告 Obagi Medical and Next Health Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
27 Jan 2026 公告 UPDATE - Obagi Medical and Alpha Aesthetic Partners Announce Their Collaboration in the ALOHA Program to Drive Real-World Evidence with Obagi® saypha® MagIQ™
27 Jan 2026 公告 Obagi Medical and Alpha Aesthetic Partners Announce Their Collaboration in the ALOHA Program to Drive Real-World Evidence with Obagi® saypha® MagIQ™
26 Jan 2026 公告 CORRECTION – Obagi Medical and Platinum Dermatology Partners Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
26 Jan 2026 公告 Obagi Medical and Platinum Dermatology Partners Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
21 Jan 2026 公告 Obagi Medical Unveils ALOHA Program to Launch Obagi® saypha® MagIQ™ – Pioneering the Largest Real-World Evaluation of a New Hyaluronic Acid Filler

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2026 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票